MedicX will report its results for the year ended 30 September 2018 in December. H218 included a significant portfolio acquisition and an important restructuring of some long-term debt facilities, increasing the company’s borrowing flexibility and extending its facilities at a lower marginal cost. NAV total return during Q3 was a strong 3.4%, following 8.0% in H118, while the pipeline of identified investment opportunities in the UK and the Republic of Ireland remained strong. The share
06 Nov 2018
MedicX Fund - Quality portfolio, performing well
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MedicX Fund - Quality portfolio, performing well
Medicx Fund (MXF:LON) | 0 0 0.0% | Mkt Cap: 426.9m
- Published:
06 Nov 2018 -
Author:
Martyn King -
Pages:
9
MedicX will report its results for the year ended 30 September 2018 in December. H218 included a significant portfolio acquisition and an important restructuring of some long-term debt facilities, increasing the company’s borrowing flexibility and extending its facilities at a lower marginal cost. NAV total return during Q3 was a strong 3.4%, following 8.0% in H118, while the pipeline of identified investment opportunities in the UK and the Republic of Ireland remained strong. The share